isoquinoline has been researched along with Malignant Melanoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, H; Cao, J; Hu, Q; Huang, S; Liu, D; Lu, B; Shen, R; Shen, X; Tao, W; Wan, H; Wang, D; Yan, Y; Yang, L; Zhang, J; Zhang, L; Zhang, M | 1 |
| Agama, KK; Antony, S; Cushman, M; Holbeck, SL; Hollingshead, M; Miao, ZH; Morrell, A; Nagarajan, M; Pommier, Y; Varticovski, L; Wright, MH | 1 |
2 other study(ies) available for isoquinoline and Malignant Melanoma
| Article | Year |
|---|---|
Discovery of EBI-907: A highly potent and orally active B-Raf(V600E) inhibitor for the treatment of melanoma and associated cancers.
Topics: Administration, Oral; Animals; Binding Sites; Cell Line, Tumor; Dogs; Drug Evaluation, Preclinical; Half-Life; Humans; Isoquinolines; Melanoma; Mice; Molecular Conformation; Molecular Dynamics Simulation; Protein Binding; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Pyrazoles; Rats; Structure-Activity Relationship; Transplantation, Heterologous | 2016 |
Bisindenoisoquinoline bis-1,3-{(5,6-dihydro-5,11-diketo-11H-indeno[1,2-c]isoquinoline)-6-propylamino}propane bis(trifluoroacetate) (NSC 727357), a DNA intercalator and topoisomerase inhibitor with antitumor activity.
Topics: Animals; Antineoplastic Agents; Catalysis; Cell Death; DNA; DNA Damage; DNA Topoisomerases, Type II; G1 Phase; Humans; Indenes; Intercalating Agents; Isoquinolines; Melanoma; Mice; Mice, Nude; Nucleic Acid Conformation; Thymidine; Topoisomerase I Inhibitors; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays | 2006 |